Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 03-Apr-20 9:02 AM View:  | Lubner David Charles Executive VP and CFO | Ra Pharmaceuticals, Inc. (RARX) | 02-Apr-20 | Disposition | 15,622 | $48.00 | $749,856.00 | (100%) 15.62K to 0 | |
| 03-Apr-20 9:01 AM View: | Farzaneh-Far Ramin Chief Medical Officer | Ra Pharmaceuticals, Inc. (RARX) | 02-Apr-20 | Disposition | 14,492 | $48.00 | $695,616.00 | (100%) 14.49K to 0 | |
| 03-Apr-20 9:02 AM View: | Treco Douglas A President and CEO Director | Ra Pharmaceuticals, Inc. (RARX) | 02-Apr-20 | Disposition | 234,707 | $48.00 | $11,265,900.00 | (100%) 234.71K to 0 | |
| 03-Apr-20 9:00 AM View: | Ra Capital Management, LLC Director 10% Owner | Ra Pharmaceuticals, Inc. (RARX) | 02-Apr-20 | Disposition | 4,858,260 | $48.00 | $233,196,000.00 | (100%) 4.86M to 0 | |
| 03-Apr-20 9:00 AM View: | Shah Rajeev M. Director 10% Owner | Ra Pharmaceuticals, Inc. (RARX) | 02-Apr-20 | Disposition Duplicate | 4,858,260 | $48.00 | $233,196,000.00 | (100%) 4.86M to 0 | |
| 03-Apr-20 9:02 AM View: | Read Simon Chief Scientific Officer | Ra Pharmaceuticals, Inc. (RARX) | 02-Apr-20 | Disposition | 12,595 | $48.00 | $604,560.00 | (100%) 12.6K to 0 | |
| 03-Apr-20 9:01 AM View: | King John C Chief Commercial Officer | Ra Pharmaceuticals, Inc. (RARX) | 02-Apr-20 | Disposition | 10,823 | $48.00 | $519,504.00 | (100%) 10.82K to 0 | |
| 03-Apr-20 9:02 AM View: | Ricardo Alonso See Remarks | Ra Pharmaceuticals, Inc. (RARX) | 02-Apr-20 | Disposition | 2,973 | $48.00 | $142,704.00 | (100%) 2.97K to 0 | |
| 03-Apr-20 9:28 AM View: | New Enterprise Associates 1... 10% Owner | Ra Pharmaceuticals, Inc. (RARX) | 02-Apr-20 | Disposition | 6,135,230 | -- | -- | (100%) 6.14M to 0 | |
| 18-Mar-20 6:00 PM View: | Ricardo Alonso See Remarks | Ra Pharmaceuticals, Inc. (RARX) | 17-Mar-20 | Private Sale (Planned) | 2,288 | $44.25 | $101,244.00 | (100%) 2.29K to 0 | |
| 18-Mar-20 6:00 PM View: | Farzaneh-Far Ramin Chief Medical Officer | Ra Pharmaceuticals, Inc. (RARX) | 16-Mar-20 | Planned Private Option Sale | 10,595 | $45.16 | $478,521.00 | (60%) 17.73K to 7.13K | |
| 18-Mar-20 6:00 PM View: | Farzaneh-Far Ramin Chief Medical Officer | Ra Pharmaceuticals, Inc. (RARX) | 16-Mar-20 | Option Exercise | 10,595 | $5.60 | $59,332.00 | 149% 7.13K to 17.73K | |
| 20-Feb-20 6:52 PM View: | Farzaneh-Far Ramin Chief Medical Officer | Ra Pharmaceuticals, Inc. (RARX) | 18-Feb-20 | Option Exercise | 10,595 | $5.60 | $59,332.00 | 149% 7.13K to 17.73K | |
| 20-Feb-20 6:52 PM View: | Farzaneh-Far Ramin Chief Medical Officer | Ra Pharmaceuticals, Inc. (RARX) | 18-Feb-20 | Planned Private Option Sale | 10,595 | $46.61 | $493,850.00 | (60%) 17.73K to 7.13K | |
| 21-Jan-20 6:32 PM View: | Ricardo Alonso See Remarks | Ra Pharmaceuticals, Inc. (RARX) | 17-Jan-20 | Private Sale (Planned) | 2,285 | $47.02 | $107,441.00 | (50%) 4.57K to 2.29K | |
| 16-Jan-20 6:01 PM View: | Farzaneh-Far Ramin Chief Medical Officer | Ra Pharmaceuticals, Inc. (RARX) | 15-Jan-20 | Option Exercise | 10,595 | $5.60 | $59,332.00 | 149% 7.13K to 17.73K | |
| 16-Jan-20 6:01 PM View: | Farzaneh-Far Ramin Chief Medical Officer | Ra Pharmaceuticals, Inc. (RARX) | 15-Jan-20 | Planned Private Option Sale | 10,595 | $46.95 | $497,441.00 | (60%) 17.73K to 7.13K | |
| 18-Dec-19 6:01 PM View: | Ricardo Alonso See Remarks | Ra Pharmaceuticals, Inc. (RARX) | 17-Dec-19 | Private Sale (Planned) | 2,285 | $47.08 | $107,568.00 | (33%) 6.86K to 4.57K | |
| 18-Dec-19 6:01 PM View: | Read Simon Chief Scientific Officer | Ra Pharmaceuticals, Inc. (RARX) | 17-Dec-19 | Planned Private Option Sale | 10,000 | $47.08 | $470,821.00 | (62%) 16.23K to 6.23K | |
| 18-Dec-19 6:01 PM View: | Read Simon Chief Scientific Officer | Ra Pharmaceuticals, Inc. (RARX) | 17-Dec-19 | Option Exercise | 10,000 | $2.87 | $28,700.00 | 160% 6.23K to 16.23K | |
| 18-Dec-19 6:00 PM View: | Farzaneh-Far Ramin Chief Medical Officer | Ra Pharmaceuticals, Inc. (RARX) | 16-Dec-19 | Planned Private Option Sale | 10,595 | $47.23 | $500,351.00 | (60%) 17.73K to 7.13K | |
| 18-Dec-19 6:00 PM View: | Farzaneh-Far Ramin Chief Medical Officer | Ra Pharmaceuticals, Inc. (RARX) | 16-Dec-19 | Option Exercise | 10,595 | $5.60 | $59,332.00 | 149% 7.13K to 17.73K | |
| 18-Nov-19 5:08 PM View: | Farzaneh-Far Ramin Chief Medical Officer | Ra Pharmaceuticals, Inc. (RARX) | 15-Nov-19 | Option Exercise | 10,595 | $5.60 | $59,332.00 | 149% 7.13K to 17.73K | |
| 18-Nov-19 5:08 PM View: | Farzaneh-Far Ramin Chief Medical Officer | Ra Pharmaceuticals, Inc. (RARX) | 15-Nov-19 | Planned Private Option Sale | 10,595 | $46.66 | $494,319.00 | (60%) 17.73K to 7.13K | |
| 18-Nov-19 5:07 PM View: | Read Simon Chief Scientific Officer | Ra Pharmaceuticals, Inc. (RARX) | 14-Nov-19 | Option Exercise | 10,000 | $2.87 | $28,700.00 | 160% 6.23K to 16.23K | |
| 18-Nov-19 5:07 PM View: | Read Simon Chief Scientific Officer | Ra Pharmaceuticals, Inc. (RARX) | 14-Nov-19 | Planned Private Option Sale | 10,000 | $46.68 | $466,808.00 | (62%) 16.23K to 6.23K | |
| 17-Oct-19 8:11 PM View: | Ricardo Alonso See Remarks | Ra Pharmaceuticals, Inc. (RARX) | 17-Oct-19 | Private Sale (Planned) | 2,285 | $46.70 | $106,710.00 | (25%) 9.14K to 6.86K | |
| 17-Oct-19 7:00 PM View: | Read Simon Chief Scientific Officer | Ra Pharmaceuticals, Inc. (RARX) | 16-Oct-19 | Option Exercise | 10,000 | $2.87 | $28,700.00 | 160% 6.23K to 16.23K | |
| 17-Oct-19 7:00 PM View: | Read Simon Chief Scientific Officer | Ra Pharmaceuticals, Inc. (RARX) | 16-Oct-19 | Planned Private Option Sale | 10,000 | $46.87 | $468,726.00 | (62%) 16.23K to 6.23K | |
| 17-Oct-19 7:00 PM View: | Farzaneh-Far Ramin Chief Medical Officer | Ra Pharmaceuticals, Inc. (RARX) | 15-Oct-19 | Option Exercise | 10,595 | $5.60 | $59,332.00 | 149% 7.13K to 17.73K | |
| 17-Oct-19 7:00 PM View: | Farzaneh-Far Ramin Chief Medical Officer | Ra Pharmaceuticals, Inc. (RARX) | 15-Oct-19 | Planned Private Option Sale | 10,595 | $46.89 | $496,769.00 | (60%) 17.73K to 7.13K | |
| 16-Sep-19 6:44 PM View: | Farzaneh-Far Ramin Chief Medical Officer | Ra Pharmaceuticals, Inc. (RARX) | 16-Sep-19 | Planned Private Option Sale | 10,595 | $25.26 | $267,675.00 | (60%) 17.73K to 7.13K | |
| 16-Sep-19 6:44 PM View: | Farzaneh-Far Ramin Chief Medical Officer | Ra Pharmaceuticals, Inc. (RARX) | 16-Sep-19 | Option Exercise | 10,595 | $5.60 | $59,332.00 | 149% 7.13K to 17.73K | |
| 16-Sep-19 6:43 PM View: | Read Simon Chief Scientific Officer | Ra Pharmaceuticals, Inc. (RARX) | 12-Sep-19 | Planned Private Option Sale | 10,000 | $25.41 | $254,050.00 | (62%) 16.23K to 6.23K | |
| 16-Sep-19 6:43 PM View: | Read Simon Chief Scientific Officer | Ra Pharmaceuticals, Inc. (RARX) | 12-Sep-19 | Option Exercise | 10,000 | $2.87 | $28,700.00 | 160% 6.23K to 16.23K | |
| 27-Aug-19 6:01 PM View: | Farzaneh-Far Ramin Chief Medical Officer | Ra Pharmaceuticals, Inc. (RARX) | 23-Aug-19 | Option Exercise | 10,595 | $5.60 | $59,332.00 | 149% 7.13K to 17.73K | |
| 27-Aug-19 6:01 PM View: | Read Simon Chief Scientific Officer | Ra Pharmaceuticals, Inc. (RARX) | 23-Aug-19 | Option Exercise | 10,000 | $2.87 | $28,700.00 | 160% 6.23K to 16.23K | |
| 27-Aug-19 6:00 PM View: | Ricardo Alonso See Remarks | Ra Pharmaceuticals, Inc. (RARX) | 23-Aug-19 | Private Sale (Planned) | 2,285 | $27.89 | $63,739.80 | (20%) 11.43K to 9.14K | |
| 27-Aug-19 6:01 PM View: | Farzaneh-Far Ramin Chief Medical Officer | Ra Pharmaceuticals, Inc. (RARX) | 23-Aug-19 | Planned Private Option Sale | 10,595 | $27.77 | $294,226.00 | (60%) 17.73K to 7.13K | |
| 27-Aug-19 6:01 PM View: | Read Simon Chief Scientific Officer | Ra Pharmaceuticals, Inc. (RARX) | 23-Aug-19 | Planned Private Option Sale | 10,000 | $27.77 | $277,703.00 | (62%) 16.23K to 6.23K | |
| 18-Jul-19 7:04 PM View: | Read Simon Chief Scientific Officer | Ra Pharmaceuticals, Inc. (RARX) | 17-Jul-19 | Option Exercise | 10,000 | $2.87 | $28,700.00 | 160% 6.23K to 16.23K | |
| 18-Jul-19 7:04 PM View: | Read Simon Chief Scientific Officer | Ra Pharmaceuticals, Inc. (RARX) | 17-Jul-19 | Planned Private Option Sale | 10,000 | $32.95 | $329,479.00 | (62%) 16.23K to 6.23K | |
| 16-Jul-19 7:15 PM View: | Farzaneh-Far Ramin Chief Medical Officer | Ra Pharmaceuticals, Inc. (RARX) | 15-Jul-19 | Planned Private Option Sale | 10,595 | $33.10 | $350,647.00 | (60%) 17.73K to 7.13K | |
| 16-Jul-19 7:15 PM View: | Farzaneh-Far Ramin Chief Medical Officer | Ra Pharmaceuticals, Inc. (RARX) | 15-Jul-19 | Option Exercise | 10,595 | $5.60 | $59,332.00 | 149% 7.13K to 17.73K | |
| 25-Jun-19 4:16 PM View: | Ricardo Alonso See Remarks | Ra Pharmaceuticals, Inc. (RARX) | 21-Jun-19 | Private Sale (Planned) | 2,857 | $23.72 | $67,781.80 | (20%) 14.29K to 11.43K | |
| 19-Jun-19 9:03 PM View: | Read Simon Chief Scientific Officer | Ra Pharmaceuticals, Inc. (RARX) | 18-Jun-19 | Planned Private Option Sale | 10,000 | $22.25 | $222,467.00 | (62%) 16.23K to 6.23K | |
| 19-Jun-19 9:03 PM View: | Read Simon Chief Scientific Officer | Ra Pharmaceuticals, Inc. (RARX) | 18-Jun-19 | Option Exercise | 10,000 | $2.87 | $28,700.00 | 160% 6.23K to 16.23K | |
| 19-Jun-19 9:03 PM View: | Farzaneh-Far Ramin Chief Medical Officer | Ra Pharmaceuticals, Inc. (RARX) | 17-Jun-19 | Market Option Sale (Planned) | 10,595 | $21.84 | $231,384.00 | (60%) 17.73K to 7.13K | |
| 19-Jun-19 9:03 PM View: | Farzaneh-Far Ramin Chief Medical Officer | Ra Pharmaceuticals, Inc. (RARX) | 17-Jun-19 | Option Exercise | 10,595 | $5.60 | $59,332.00 | 149% 7.13K to 17.73K | |
| 18-Apr-19 5:55 PM View: | King John C Chief Commercial Officer | Ra Pharmaceuticals, Inc. (RARX) | 16-Apr-19 | Payment of Exercise | 4,506 | $21.93 | $98,816.60 | (29%) 15.33K to 10.82K |
